Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety Study of Regimens of PSI-352938, PSI-7977, and Ribavirin in Patients With Chronic Hepatitis C Infection (QUANTUM)
This study is ongoing, but not recruiting participants.
Study NCT01435044   Information provided by Gilead Sciences

First Received on September 9, 2011.   Last Updated on June 7, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis C, Chronic
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis, Chronic
More general conditions related to this trial
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
PSI-352938
PSI-352938 and PSI-7977
PSI-7977 with ribavirin
PSI-7977 and ribavirin 12 Weeks
Additional drug interventions recognized in this trial
Ribavirin
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antiviral Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Gilead Sciences
Quintiles


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services